Cardinal Health, Inc. CAH
Verdict: Sell. Fair value $193 against a price of $205 on 6 Jan 2026, 6% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net income has swung dramatically from a loss of $-0.94B in 2022 to a profit of $1.56B in 2025..... The OCF / Net Income ratio, while still healthy, has shown a sharp declining trend from 8.62 in....
Main risks
- Negative Stockholders' Equity (-$2.78B): A critical red flag indicating liabilities exceed assets. This suggests technical insolvency, makes key ratios like ROE and Debt/Equity meaningless, and signals significant financial risk, potentially from historical losses or aggressive buybacks.
- Extremely Thin and Volatile Margins: The estimated TTM operating margin is just 1.8% and 2024 net margin was 0.4%. This provides no cushion for operational issues or pricing pressure and has led to net losses in the recent past (2022: -$0.94B).
- Distorted and Unreliable Return Metrics: The negative equity base makes standard return metrics like ROE and ROIC mathematically invalid and misleading. The calculated ROIIC of 83.5% is likely a statistical artifact of a shrinking capital base rather than a sign of true economic return.
- Net income has swung dramatically from a loss of $-0.94B in 2022 to a profit of $1.56B in 2025....
- Intense competitive environment
- Net income has swung dramatically from a loss of $-0.94B in 2022 to a profit of $1.56B in 2025. This level of volatility suggests that large, non-recurring items are significantly impacting reported earnings, making year-over-year comparisons difficult and potentially obscuring the core operational performance.